









Markets
/
Stocks
/
nasdaq-mnkd
/

MannKind Corp

MNKD

5.250USD

-0.170-3.14%

Close 11/11, 16:00（ET）Quotes delayed by 15 min

1.61BMarket Cap

55.14P/E TTM



MannKind Corp

5.250

-0.170-3.14%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of MannKind Corp

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

MannKind Corp's Score

Industry at a Glance

Industry Ranking

81 / 407

Overall Ranking

186 / 4608

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.063

Target Price

+67.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

MannKind Corp Highlights

StrengthsRisks

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 186.16% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 53.52, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 171.20M shares, decreasing 8.44% quarter-over-quarter.

Held by Joel Greenblatt

Star Investor Joel Greenblatt holds 71.19K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 8.74, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 82.13M, representing a year-over-year increase of 17.20%, while its net profit experienced a year-over-year increase of 30.87%.

Score

Industry at a Glance

Previous score

8.74

Change



Financials

5.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

MannKind Corp's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 4.66, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 53.52, which is 219.87% below the recent high of 171.19 and 320.25% above the recent low of -117.87.

Score

Industry at a Glance

Previous score

4.66

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 8.75, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for MannKind Corp is 9.50, with a high of 11.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

9.063

Target Price

+67.20%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

MannKind Corp

MNKD

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 6.92, which is higher than the Biotechnology & Medical Research industry's average of 6.78. Sideways: Currently, the stock price is trading between the resistance level at 6.01 and the support level at 4.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.13

Change

-0.21

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.052

Neutral

RSI(14)

45.019

Neutral

STOCH(KDJ)(9,3,3)

32.688

Sell

ATR(14)

0.318

High Vlolatility

CCI(14)

-116.124

Sell

Williams %R

76.744

Sell

TRIX(12,20)

0.199

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

5.612

Sell

MA10

5.570

Sell

MA20

5.490

Sell

MA50

5.450

Sell

MA100

4.671

Buy

MA200

4.774

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 55.75%, representing a quarter-over-quarter decrease of 7.24%. The largest institutional shareholder is The Vanguard, holding a total of 17.57M shares, representing 5.72% of shares outstanding, with 8.36% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

23.58M

+9.93%

The Vanguard Group, Inc.

Star Investors

18.10M

+4.86%

State Street Investment Management (US)

10.75M

+13.47%

Geode Capital Management, L.L.C.

7.62M

+12.25%

Nitorum Capital, L.P.

7.01M

-9.94%

Two Sigma Investments, LP

5.91M

-16.80%

Avoro Capital Advisors LLC

5.85M

-33.14%

Millennium Management LLC

4.48M

-23.03%

Qube Research & Technologies Ltd

4.07M

+25.48%

Dimensional Fund Advisors, L.P.

4.05M

+15.00%

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 4.77, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.82. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.